New Treatment Significantly Improves Survival Rates for Children with Standard-Risk B-ALL
Philadelphia, PA – A groundbreaking new study suggests innovative immunotherapy drug blinatumomab coupled with chemotherapy significantly improves survival rates in children diagnosed with standard-risk (SR) B-acute Lymphoblastic Leukemia (ALL
